TG Therapeutics Inc (TGTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $56.87 (+0.71%), Market cap $6.53B, P/E ratio 14.91, 52-week low–high $26.39 ~ $43.14.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK
Financial statements, price targets, institutional (13F) holdings and related news for TG Therapeutics Inc are updated in real time on BlackAll Trade.
TG Therapeutics Inc trades at $56.87 (+0.71%). Real-time quotes and charts are available on BlackAll Trade.
TG Therapeutics Inc has a market cap of about $6.53B. Its P/E ratio is 14.91.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United State